About Wegovy (Semaglutide 2.4mg)
Wegovy contains semaglutide, the same active ingredient found in Ozempic, but at a higher dose specifically designed for weight management. It is FDA-approved for long-term use in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Unlike short-term diet pills, Wegovy is meant to be used as part of a medically supervised program that includes healthy eating and regular exercise.
When prescribed appropriately, semaglutide helps reduce appetite, slows down how quickly food leaves your stomach, and regulates the satiety signals in your brain. The practical result is that most patients eat meaningfully less without the constant mental effort that comes with strict dieting on its own.
How Wegovy Works in Your Body
GLP-1 Receptor Activation
Semaglutide mimics the GLP-1 hormone your body naturally releases after eating. This helps regulate both appetite and blood sugar levels.
Delayed Gastric Emptying
Food leaves your stomach more slowly, which means you feel full longer and are satisfied with smaller portions than before.
Central Appetite Regulation
Semaglutide acts on appetite centers in the hypothalamus, reducing both cravings and emotional eating patterns that make weight loss so difficult.
Cardiovascular Protection
The 2023 SELECT trial showed that Wegovy reduced major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo in adults with obesity and established heart disease.
Wegovy Weight Loss Results (STEP-1 Trial)
The STEP-1 trial is the landmark study that led to Wegovy's FDA approval. It was a 68-week, double-blind, placebo-controlled phase 3 trial. All participants followed a reduced-calorie diet and exercised more. Here is what the data showed.
| Group | Avg Weight Lost | Lost 15% or More | Lost 20% or More |
|---|
| Placebo | 2.6% | 5% | 2% |
| Semaglutide 2.4mg (Wegovy) | 15.3% | 50% | 30% |
Source: Wilding JPH et al. N Engl J Med. 2021;384:989-1002. Results with diet and exercise. Individual results vary.
SELECT Trial 2023: Cardiovascular Risk Reduction
The SELECT cardiovascular outcomes trial enrolled 17,604 patients across 33 countries. It found that Wegovy (semaglutide 2.4mg) reduced the risk of heart attack, stroke, or cardiovascular death by 20% compared to placebo in adults with obesity and established cardiovascular disease. This was the first weight loss medication ever to show significant cardiovascular protection in a large outcomes trial.
What to Expect: Wegovy Weight Loss Timeline
| Timeframe | What Typically Happens |
|---|
| Weeks 1 to 4 | You start on the 0.25mg dose. Appetite changes begin. Some nausea is possible as your body adjusts. Weight loss of 1 to 4 lbs is typical. |
| Months 2 to 3 | Dose escalates to 0.5mg, then 1.0mg. Appetite suppression becomes more noticeable. Cumulative loss of 5 to 10 lbs is typical. |
| Months 4 to 5 | Dose reaches 1.7mg or the full 2.4mg maintenance level. Body composition changes become visible. Cumulative loss of 10 to 18+ lbs is typical. |
| Months 6 to 12 | Continued weight loss toward plateau. The average loss in the STEP-1 trial at 68 weeks was 15.3%, roughly 34 lbs for someone starting at 220 lbs. |
Wegovy vs Mounjaro vs Ozempic: Key Differences
All three are injectable GLP-1 based therapies, but they differ in how they work, what they are approved for, how much weight loss they produce, and how they are dosed. Your prescriber will choose the right one based on your full health picture.
| Feature | Wegovy | Mounjaro | Ozempic |
|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist | GLP-1 receptor agonist |
| FDA weight loss approval | Yes (Wegovy) | Yes (as Zepbound) | No (diabetes only, off-label for weight loss) |
| Avg weight loss (trial) | 15.3% (STEP-1, 68 wk) | 22.5% at 15mg (SURMOUNT-1, 72 wk) | 6 to 9% (diabetes trial doses) |
| Max dose | 2.4mg/week | 15mg/week | 2mg/week |
| CV outcomes data | Yes, 20% reduction (SELECT) | Ongoing (SURMOUNT-MMO) | Yes (SUSTAIN-6, diabetes trial) |
Mounjaro's higher average weight loss in trials is partly due to its dual GIP/GLP-1 mechanism. Head-to-head comparison trials between Wegovy and Mounjaro are still underway. Your prescriber will select the most appropriate option for your situation.
How to Use Wegovy
Administration Basics
- Form: Single-use pre-filled subcutaneous pen.
- Frequency: Once weekly, on the same day each week.
- Injection sites: Abdomen, thigh, or upper arm. Rotate sites each week.
- Timing: Any time of day, with or without food.
- Storage: Refrigerate at 36 to 46 degrees F (2 to 8 degrees C). Do not freeze.
Standard Wegovy Dose Escalation Schedule
| Week | Dose | Purpose |
|---|
| 1 to 4 | 0.25mg once weekly | Starter dose. Helps reduce GI side effects during the adjustment period. |
| 5 to 8 | 0.5mg once weekly | Gradual escalation if the lower dose is tolerated well. |
| 9 to 12 | 1.0mg once weekly | Monitor weight, appetite changes, and any side effects. |
| 13 to 16 | 1.7mg once weekly | Higher dose if needed and tolerated by the patient. |
| 17 onward | 2.4mg once weekly | Target maintenance dose. This is the dose used in the STEP-1 trial. |
What to do if you miss a dose: If your next scheduled dose is more than 5 days away, inject as soon as you remember. If it is less than 5 days until your next dose, skip the missed one and inject on your regular day. Never take two doses at the same time.
Important Safety Information for Wegovy
This is not complete safety information. Always review the full Medication Guide and talk with your healthcare provider before starting, stopping, or changing any medication.
Do Not Use Wegovy If:
- You or a family member has a history of medullary thyroid carcinoma (MTC).
- You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- You are allergic to semaglutide or any ingredient in Wegovy.
- You are pregnant or planning to become pregnant in the near future.
Common Side Effects
The most common side effects include nausea, vomiting, diarrhea, constipation, stomach pain, and reactions at the injection site. These tend to be worst during the dose escalation phase and usually improve over time. More serious risks include pancreatitis, gallbladder problems, kidney issues, and low blood sugar (especially if you also take other diabetes medicines). Make sure your prescriber knows about all the medications you currently take.
Call your healthcare provider right away if you experience severe stomach pain, signs of an allergic reaction, symptoms of very low blood sugar, or any other side effect your clinician has told you to watch for.
Frequently Asked Questions About Wegovy
In the STEP-1 trial, adults taking semaglutide 2.4mg lost an average of 15.3% of their starting body weight over 68 weeks. That works out to roughly 34 lbs for someone who starts at 220 lbs. About one in three participants lost 20% or more. Your results will depend on your dose, how long you take it, your diet, and your activity level.
They both contain semaglutide, but they are not the same product. Wegovy is approved specifically for weight management and goes up to 2.4mg per week. Ozempic is approved for type 2 diabetes and tops out at 2mg per week. The higher dose in Wegovy tends to produce better weight loss results in clinical trials.
In separate phase 3 trials, Mounjaro (tirzepatide) produced higher average weight loss, up to 22.5% at the 15mg dose in the SURMOUNT-1 trial over 72 weeks. Wegovy produced 15.3% in the STEP-1 trial over 68 weeks. Head-to-head trials are still ongoing. Your prescriber will help you choose based on your health profile and treatment history.
Yes. Through Vitercure, a licensed clinician reviews your medical history through our HIPAA-compliant telehealth platform. If Wegovy is clinically appropriate for you, they can issue a valid prescription without an in-person visit. No medication is dispensed without a completed clinical evaluation.
Research shows that many people regain a significant portion of lost weight after stopping semaglutide, especially if they have not made lasting lifestyle changes. You should never stop Wegovy abruptly without talking to your clinician first. They can help you plan a safe transition or adjust your dose gradually.
Yes. Wegovy is approved for use alongside a reduced-calorie diet and regular physical activity. The good news is that the appetite suppression it provides makes it much easier for most people to stick with a calorie deficit. Think of it as a tool that works best when combined with healthy habits.
